HQ Team
September 29, 2023: Pfizer announced the availability of its migraine management drug Rimegepant in Hong Kong — the company’s first market in Asia.
Results from the end-stage trials have demonstrated that a single dose of Rimegepant provided a superior reduction in pain and associated symptoms of migraine at two hours compared to placebo.
Rimegepant has been sold in over 39 markets to date, including in the United States, the European Union and the United Kingdom.
Additional regulatory applications are under review around the world, according to a Pfizer statement released through PRNewswire.
More than one billion people worldwide live with migraine, and it is classified as the second leading cause of disability in the world.
Debilitating headache
Migraine is characterized by debilitating headache attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia).
Rimegepant targets a key component of migraine by blocking calcitonin gene-related peptide receptors (CGRP). The increase in CGRP leads to blood vessel dilation, causing migraine attacks.
The global migraine drugs market size is estimated to grow by $1.2 billion at a compound annual growth rate of 6.05% between 2022 and 2027, according to research firm Technavio.
New classes of drugs with higher clinical efficacy, such as calcitonin gene-related peptide (CGRP) and monoclonal antibodies, are expected to provide growth momentum to the growth of the global migraine drugs market during the forecast period.
Key players in the migraine market include Abbott Laboratories, Amgen Inc. AstraZeneca, Bayer AG, Dr Reddys Laboratories Ltd., Eli Lilly and Co., and GlaxoSmithKline Plc.
